Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes (Q60045997)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

3 references

30 January 2021

4 February 2021

24 August 2022

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

main subject

cardiovascular disease

6 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

18 November 2019

3 references

2 October 2019

18 November 2019

4 February 2021

1 reference

2 October 2019

1 reference

18 November 2019

1 reference

30 January 2021

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

author name string

Jessica W Skelley

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

Brooke S Carter

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

language of work or name

English

0 references

publication date

7 December 2018

10 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

18 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

30 January 2021

4 February 2021

24 August 2022

Vascular Health and Risk Management

10 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

18 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

30 January 2021

4 February 2021

24 August 2022

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

page(s)

419-428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial

15 April 2020

copyright license

9 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

18 November 2019

30 January 2021

4 February 2021

24 August 2022

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

1 reference

12 December 2020

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

12 December 2020

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

12 December 2020

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

12 December 2020

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

12 December 2020

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

1 reference

12 December 2020

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

12 December 2020

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

12 December 2020

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

1 reference

12 December 2020

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

1 reference

12 December 2020

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

1 reference

12 December 2020

Assessment of cardiovascular risk in hypertensive patients: a comparison of commonly used risk scoring programs

1 reference

12 December 2020

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

1 reference

12 December 2020

Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

1 reference

12 December 2020

Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

1 reference

12 December 2020

Sodium-glucose cotransport

1 reference

12 December 2020

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

1 reference

12 December 2020

SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery

1 reference

12 December 2020

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

12 December 2020

Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension

1 reference

12 December 2020

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.

1 reference

12 December 2020

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

1 reference

12 December 2020

Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys

1 reference

12 December 2020

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

1 reference

12 December 2020

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

1 reference

12 December 2020

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis

1 reference

12 December 2020

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot

1 reference

12 December 2020

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

12 December 2020

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

1 reference

12 December 2020

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

1 reference

12 December 2020

In-hospital costs of diabetic foot disease treated by a multidisciplinary foot team

1 reference

12 December 2020

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.

1 reference

12 December 2020

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

1 reference

12 December 2020

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?

1 reference

12 December 2020

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

1 reference

12 December 2020

14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018.

1 reference

12 December 2020

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

1 reference

12 December 2020

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.

1 reference

12 December 2020

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.

1 reference

12 December 2020

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

1 reference

12 December 2020

Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril

1 reference

12 December 2020

Identifiers

DOI

10.2147/VHRM.S168472

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573964%20AND%20SRC:MED&resulttype=core&format=json

15 April 2020

1 reference